1. Lapointe S, Perry A, Butowski NA. Primary brain tumours in adults. Lancet. 2018;392(10145):432–446. doi:10.1016/S0140-6736(18)30990-5. [PubMed] [CrossRef] [Google Scholar]
2. Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol. 2005;109(1):93–108. doi:10.1007/s00401-005-0991-y. [PubMed] [CrossRef] [Google Scholar]
3. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321(5897):1807–1812. doi:10.1126/science.1164382. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
4. Kayabolen A, Yilmaz E, Bagci-Onder T. IDH mutations in glioma: double-edged sword in clinical applications? Biomedicines. 2021;9(7):799. doi:10.3390/biomedicines9070799. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
5. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol. 2009;174(4):1149–1153. doi:10.2353/ajpath.2009.080958. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
6. Cohen AL, Holmen SL, Colman H. IDH1 and IDH2 mutations in gliomas. Curr Neurol Neurosci Rep. 2013;13(5):345. doi:10.1007/s11910-013-0345-4. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
7. Zong H, Verhaak RGW, Canoll P. The cellular origin for malignant glioma and prospects for clinical advancements. Expert Rev Mol Diagn. 2012;12(4):383–394. doi:10.1586/erm.12.30. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
8. Claus EB, Walsh KM, Wiencke JK, Molinaro AM, Wiemels JL, Schildkraut JM, et al. Survival and low-grade glioma: the emergence of genetic information. Neurosurg Focus. 2015;38(1):E6. doi:10.3171/2014.10.FOCUS12367. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
9. Leu S, von Felten S, Frank S, Vassella E, Vajtai I, Taylor E, et al. IDH/MGMT-driven molecular classification of low-grade glioma is a strong predictor for long-term survival. Neuro Oncol. 2013;15(4):469–479. doi:10.1093/neuonc/nos317. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
10. Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23(8):1231–1251. doi:10.1093/neuonc/noab106. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
11. MJvd B, Smits M, Kros JM, Chang SM. Diffuse infiltrating oligodendroglioma and astrocytoma. J Clin Oncol. 2017;35(21):2394–2401. doi:10.1200/JCO.2017.72.6737. [PubMed] [CrossRef] [Google Scholar]
12. Bush NAO, Chang S. Treatment strategies for low-grade glioma in adults. J Oncol Pract. 2016;12(12):1235–1241. doi:10.1200/JOP.2016.018622. [PubMed] [CrossRef] [Google Scholar]
13. Schiff D. Low-grade gliomas. CONTIN: Lifelong Learn Neurol. 2015;21(2):345–354. [PubMed] [Google Scholar]
14. Liu R, Page M, Solheim K, Fox S, Chang SM. Quality of life in adults with brain tumors: current knowledge and future directions. Neuro-oncology. 2009;11(3):330–339. doi:10.1215/15228517-2008-093. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
15. Louis DN. WHO classification of tumours of the central nervous system. WHO Regional Office Europe; 2007. [Google Scholar]
16. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97–109. doi:10.1007/s00401-007-0243-4. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
17. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathologica. 2016;131(6):803–820. doi:10.1007/s00401-016-1545-1. [PubMed] [CrossRef] [Google Scholar]
18. Perry A, Wesseling P. Histologic classification of gliomas. Handb Clin Neurol. 2016;134:71–95. doi:10.1016/B978-0-12-802997-8.00005-0. [PubMed] [CrossRef] [Google Scholar]
19. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765–773. doi:10.1056/NEJMoa0808710. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
20. Han S, Liu Y, Cai SJ, Qian M, Ding J, Larion M, et al. IDH mutation in glioma: molecular mechanisms and potential therapeutic targets. Br J Cancer. 2020;122(11):1580–1589. doi:10.1038/s41416-020-0814-x. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
21. Dang L, Su SM. Isocitrate dehydrogenase mutation and (r)-2-hydroxyglutarate: from basic discovery to therapeutics development. Annu Rev Biochem. 2017;86:305–331. doi:10.1146/annurev-biochem-061516-044732. [PubMed] [CrossRef] [Google Scholar]
22. Parker SJ, Metallo CM. Metabolic consequences of oncogenic IDH mutations. Pharmacol Ther. 2015;152:54–62. doi:10.1016/j.pharmthera.2015.05.003. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
23. Yen KE, Bittinger MA, Su SM, Fantin VR. Cancer-associated IDH mutations: biomarker and therapeutic opportunities. Oncogene. 2010;29(49):6409–6417. doi:10.1038/onc.2010.444. [PubMed] [CrossRef] [Google Scholar]
24. Wen PY, Packer RJ. The 2021 WHO classification of tumors of the central nervous system: clinical implications. Neuro-Oncology. 2021;23(8):1215–1217. doi:10.1093/neuonc/noab120. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
25. Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012. Neuro Oncol. 2015;17(suppl_4):iv1–iv62. doi:10.1093/neuonc/nov189. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
26. Miller JJ, Gonzalez Castro LN, McBrayer S, Weller M, Cloughesy T, Portnow J, et al. Isocitrate dehydrogenase (IDH) mutant gliomas: a Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions. Neuro-Oncology. 2022;25(1):4–25. doi:10.1093/neuonc/noac207. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
27. Gonzalez Castro LN, Milligan TA. Seizures in patients with cancer. Cancer. 2020;126(7):1379–1389. doi:10.1002/cncr.32708. [PubMed] [CrossRef] [Google Scholar]
28. Whittle IR. The dilemma of low grade glioma. J Neurol Neurosurg Psychiatry. 2004;75 Suppl 2(Suppl 2):ii31–ii36. [PMC free article] [PubMed] [Google Scholar]
29. Grier JT, Batchelor T. low-grade gliomas in adults. The Oncologist. 2006;11(6):681–693. doi:10.1634/theoncologist.11-6-681. [PubMed] [CrossRef] [Google Scholar]
30. Behin A, Hoang-Xuan K, Carpentier AF, Delattre J-Y. Primary brain tumours in adults. The Lancet. 2003;361(9354):323–331. doi:10.1016/S0140-6736(03)12328-8. [PubMed] [CrossRef] [Google Scholar]
31. Sabha N, Knobbe CB, Maganti M, Al Omar S, Bernstein M, Cairns R, et al. Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas. Neuro Oncol. 2014;16(7):914–923. doi:10.1093/neuonc/not299. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
32. Juratli TA, Kirsch M, Geiger K, Klink B, Leipnitz E, Pinzer T, et al. The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas. J Neurooncol. 2012;110(3):325–333. doi:10.1007/s11060-012-0977-2. [PubMed] [CrossRef] [Google Scholar]
33. Kizilbash SH, Giannini C, Voss JS, Decker PA, Jenkins RB, Laack NN, et al. Impact of adjuvant temozolomide and IDH mutation status among patients with anaplastic astrocytoma. American Society of Clinical Oncology; 2013. [PMC free article] [PubMed] [Google Scholar]
34. Juratli TA, Cahill DP, McCutcheon IE. Determining optimal treatment strategy for diffuse glioma: the emerging role of IDH mutations. Expert Rev Anticancer Ther. 2015;15(6):603–606. doi:10.1586/14737140.2015.1047351. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
35. Wen PY, Kesari S. Malignant Gliomas in Adults. N Engl J Med. 2008;359(5):492–507. doi:10.1056/NEJMra0708126. [PubMed] [CrossRef] [Google Scholar]
36. Whittle IR. What is the place of conservative management for adult supratentorial low-grade glioma? Adv Tech Stand Neurosurg. 2010;35:65–79. doi:10.1007/978-3-211-99481-8_3. [PubMed] [CrossRef] [Google Scholar]
37. Jakola AS, Skjulsvik AJ, Myrmel KS, Sjåvik K, Unsgård G, Torp SH, et al. Surgical resection versus watchful waiting in low-grade gliomas. Ann Oncol. 2017;28(8):1942–1948. doi:10.1093/annonc/mdx230. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
38. Aghi MK, Nahed BV, Sloan AE, Ryken TC, Kalkanis SN, Olson JJ. The role of surgery in the management of patients with diffuse low grade glioma: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2015;125(3):503–530. doi:10.1007/s11060-015-1867-1. [PubMed] [CrossRef] [Google Scholar]
39. Jakola AS, Myrmel KS, Kloster R, Torp SH, Lindal S, Unsgård G, et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in low-grade gliomas. Jama. 2012;308(18):1881–1888. doi:10.1001/jama.2012.12807. [PubMed] [CrossRef] [Google Scholar]
40. Muragaki Y, Chernov M, Maruyama T, Ochiai T, Taira T, Kubo O, et al. Low-grade glioma on stereotactic biopsy: how often is the diagnosis accurate? Minim Invasive Neurosurg. 2008;51(5):275–279. doi:10.1055/s-0028-1082322. [PubMed] [CrossRef] [Google Scholar]
41. Jackson RJ, Fuller GN, Abi-Said D, Lang FF, Gokaslan ZL, Shi WM, et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro-oncology. 2001;3(3):193–200. doi:10.1093/neuonc/3.3.193. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
42. McGirt MJ, Chaichana KL, Gathinji M, Attenello FJ, Than K, Olivi A, et al. Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J Neurosurg. 2009;110(1):156–162. doi:10.3171/2008.4.17536. [PubMed] [CrossRef] [Google Scholar]
43. Smith JS, Chang EF, Lamborn KR, Chang SM, Prados MD, Cha S, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol. 2008;26(8):1338–1345. doi:10.1200/JCO.2007.13.9337. [PubMed] [CrossRef] [Google Scholar]
44. Wijnenga MMJ, French PJ, Dubbink HJ, Dinjens WNM, Atmodimedjo PN, Kros JM, et al. The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis. Neuro Oncol. 2018;20(1):103–112. doi:10.1093/neuonc/nox176. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
45. de Leeuw CN, Vogelbaum MA. Supratotal resection in glioma: a systematic review. Neuro-Oncology. 2018;21(2):179–188. doi:10.1093/neuonc/noy166. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
46. Rossi M, Ambrogi F, Gay L, Gallucci M, Conti Nibali M, Leonetti A, et al. Is supratotal resection achievable in low-grade gliomas? Feasibility, putative factors, safety, and functional outcome. J Neurosurg. 2020;132(6):1692–1705. doi:10.3171/2019.2.JNS183408. [PubMed] [CrossRef] [Google Scholar]
47. Karschnia P, Vogelbaum MA, van den Bent M, Cahill DP, Bello L, Narita Y, et al. Evidence-based recommendations on categories for extent of resection in diffuse glioma. Eur J Cancer. 2021;149:23–33. doi:10.1016/j.ejca.2021.03.002. [PubMed] [CrossRef] [Google Scholar]
48. Beiko J, Suki D, Hess KR, Fox BD, Cheung V, Cabral M, et al. IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro-oncology. 2014;16(1):81–91. doi:10.1093/neuonc/not159. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
49. Kawaguchi T, Sonoda Y, Shibahara I, Saito R, Kanamori M, Kumabe T, et al. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion. J Neurooncol. 2016;129(3):505–514. doi:10.1007/s11060-016-2201-2. [PubMed] [CrossRef] [Google Scholar]
50. Douw L, Klein M, fa*gel SS, van den Heuvel J, Taphoorn MJ, Aaronson NK, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol. 2009;8(9):810–818. doi:10.1016/S1474-4422(09)70204-2. [PubMed] [CrossRef] [Google Scholar]
51. Lanese A, Franceschi E, Brandes AA. The risk assessment in low-grade gliomas: an analysis of the european organization for research and treatment of cancer (eortc) and the radiation therapy oncology group (RTOG) criteria. Oncol Ther. 2018;6(2):105–108. doi:10.1007/s40487-018-0063-9. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
52. Shaw EG, Berkey B, Coons SW, Brachman D, Buckner JC, Stelzer KJ, et al. Initial report of radiation therapy oncology group (rtog) 9802: prospective studies in adult low-grade glioma (lgg) J Clin Oncol. 2006;24(18_suppl):1500. doi:10.1200/jco.2006.24.18_suppl.1500. [CrossRef] [Google Scholar]
53. van den Bent MJ, Afra D, de Witte O, Hassel MB, Schraub S, Hoang-Xuan K, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. The Lancet. 2005;366(9490):985–990. doi:10.1016/S0140-6736(05)67070-5. [PubMed] [CrossRef] [Google Scholar]
54. Mohile NA, Messersmith H, Gatson NT, Hottinger AF, Lassman A, Morton J, et al. Therapy for diffuse astrocytic and oligodendroglial tumors in adults: asco-sno guideline. J Clin Oncol. 2021;40(4):403–426. doi:10.1200/JCO.21.02036. [PubMed] [CrossRef] [Google Scholar]
55. Shih HA, Sherman JC, Nachtigall LB, Colvin MK, Fullerton BC, Daartz J, et al. Proton therapy for low-grade gliomas: Results from a prospective trial. Cancer. 2015;121(10):1712–1719. doi:10.1002/cncr.29237. [PubMed] [CrossRef] [Google Scholar]
56. Mason WP, Krol GS, DeAngelis LM. Low-grade oligodendroglioma responds to chemotherapy. Neurology. 1996;46(1):203–207. doi:10.1212/WNL.46.1.203. [PubMed] [CrossRef] [Google Scholar]
57. Buckner JC, Gesme D, Jr, O’Fallon JR, Hammack JE, Stafford S, Brown PD, et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J clin oncol. 2003;21(2):251–255. doi:10.1200/JCO.2003.06.023. [PubMed] [CrossRef] [Google Scholar]
58. Quinn JA, Reardon DA, Friedman AH, Rich JN, Sampson JH, Provenzale JM, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma. J clin oncol. 2003;21(4):646–651. doi:10.1200/JCO.2003.01.009. [PubMed] [CrossRef] [Google Scholar]
59. Brada M, Viviers L, Abson C, Hines F, Britton J, Ashley S, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Annals of oncology. 2003;14(12):1715–1721. doi:10.1093/annonc/mdg371. [PubMed] [CrossRef] [Google Scholar]
60. Cairncross JG, Macdonald DR. Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol. 1988;23(4):360–364. doi:10.1002/ana.410230408. [PubMed] [CrossRef] [Google Scholar]
61. Bell EH, Zhang P, Shaw EG, Buckner JC, Barger GR, Coons SW, et al. ACTR-37. Predictive significance of idh1/2 mutation and 1p/19q co-deletion status in a post-hoc analysis of nrg oncology/rtog 9802: a phase iii trial of rt vs rt + pcv in high risk low-grade gliomas. Neuro-Oncol. 2017;19(suppl_6):vi8–vvi. doi:10.1093/neuonc/nox168.028. [CrossRef] [Google Scholar]
62. Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J clinical oncol. 2013;31(3):337. doi:10.1200/JCO.2012.43.2674. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
63. van den Bent MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre J-Y, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J clin oncol. 2013;31(3):344–350. doi:10.1200/JCO.2012.43.2229. [PubMed] [CrossRef] [Google Scholar]
64. van den Bent MJ, Baumert B, Erridge SC, Vogelbaum MA, Nowak AK, Sanson M, et al. Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. The Lancet. 2017;390(10103):1645–1653. doi:10.1016/S0140-6736(17)31442-3. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
65. van den Bent MJ, Tesileanu CMS, Wick W, Sanson M, Brandes AA, Clement PM, et al. Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study. Lancet Oncol. 2021;22(6):813–823. doi:10.1016/S1470-2045(21)00090-5. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
66. Jaeckle KA, Ballman KV, van den Bent M, Giannini C, Galanis E, Brown PD, et al. CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design. Neuro Oncol. 2021;23(3):457–467. doi:10.1093/neuonc/noaa168. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
67. Nabors LB, Portnow J, Ammirati M, Baehring J, Brem H, Butowski N, et al. NCCN guidelines insights: central nervous system cancers, version 1.2017. J Natl Compr Canc Netw. 2017;15(11):1331–1345. doi:10.6004/jnccn.2017.0166. [PubMed] [CrossRef] [Google Scholar]
68. Rohle D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C, Campos C, et al. An inhibitor of mutant idh1 delays growth and promotes differentiation of glioma cells. Science. 2013;340(6132):626–630. doi:10.1126/science.1236062. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
69. Popovici-Muller J, Lemieux RM, Artin E, Saunders JO, Salituro FG, Travins J, et al. Discovery of AG-120 (Ivosidenib): a first-in-class mutant IHD1 inhibitor for the treatment of IHD1 mutant cancers. ACS Med Chem Lett. 2018;9(4):300–305. doi:10.1021/acsmedchemlett.7b00421. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
70. Okoye-Okafor UC, Bartholdy B, Cartier J, Gao EN, Pietrak B, Rendina AR, et al. New IDH1 mutant inhibitors for treatment of acute myeloid leukemia. Nat Chem Biol. 2015;11(11):878–886. doi:10.1038/nchembio.1930. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
71. Mellinghoff IK, Penas-Prado M, Peters KB, Burris HA, 3rd, Maher EA, Janku F, et al. vorasidenib, a dual inhibitor of mutant IHD1/2, in recurrent or progressive glioma; results of a first-in-human phase i trial. Clin Cancer Res. 2021;27(16):4491–4499. doi:10.1158/1078-0432.CCR-21-0611. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
72. Mellinghoff IK, Ellingson BM, Touat M, Maher E, De La Fuente MI, Holdhoff M, et al. Ivosidenib in isocitrate dehydrogenase 1-mutated advanced glioma. J Clin Oncol. 2020;38(29):3398–3406. doi:10.1200/JCO.19.03327. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
73. de la Fuente MI, Colman H, Rosenthal M, Van Tine BA, Levacic D, Walbert T, et al. Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: a multicenter, open-label, phase 1b/2 trial. Neuro Oncol. 2022; [PMC free article] [PubMed]
74. Wick A, Bähr O, Schuler M, Rohrberg K, Chawla SP, Janku F, et al. Phase I assessment of safety and therapeutic activity of bay1436032 in patients with idh1-mutant solid tumors. Clin Cancer Res. 2021;27(10):2723–2733. doi:10.1158/1078-0432.CCR-20-4256. [PubMed] [CrossRef] [Google Scholar]
75. Natsume A, Arakawa Y, Narita Y, Sugiyama K, Hata N, Muragaki Y, et al. The first-in-human phase I study of a brain penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas. Neuro Oncol. 2022; [PMC free article] [PubMed]
76. Johannessen TA, Mukherjee J, Viswanath P, Ohba S, Ronen SM, Bjerkvig R, et al. Rapid conversion of mutant idh1 from driver to passenger in a model of human gliomagenesis. Mol Cancer Res. 2016;14(10):976–983. doi:10.1158/1541-7786.MCR-16-0141. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
77. Turcan S, Makarov V, Taranda J, Wang Y, Fabius AWM, Wu W, et al. Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence. Nat Genet. 2018;50(1):62–72. doi:10.1038/s41588-017-0001-z. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
78. Sulkowski PL, Corso CD, Robinson ND, Scanlon SE, Purshouse KR, Bai H, et al. 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses hom*ologous recombination and induces PARP inhibitor sensitivity. Sci Transl Med. 2017;9(375) [PMC free article] [PubMed]
79. Molenaar RJ, Botman D, Smits MA, Hira VV, van Lith SA, Stap J, et al. Radioprotection of IDH1-mutated cancer cells by the idh1-mutant inhibitor agi-5198idh1r132h inhibition radioprotects idh1r132h cells. Cancer research. 2015;75(22):4790–4802. doi:10.1158/0008-5472.CAN-14-3603. [PubMed] [CrossRef] [Google Scholar]
80. Flavahan WA, Drier Y, Liau BB, Gillespie SM, Venteicher AS, Stemmer-Rachamimov AO, et al. Insulator dysfunction and oncogene activation in IDH mutant gliomas. Nature. 2016;529(7584):110–114. doi:10.1038/nature16490. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
81. Turcan S, Fabius AW, Borodovsky A, Pedraza A, Brennan C, Huse J, et al. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine. Oncotarget. 2013;4(10):1729–1736. doi:10.18632/oncotarget.1412. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
82. Borodovsky A, Salmasi V, Turcan S, Fabius AW, Baia GS, Eberhart CG, et al. 5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft. Oncotarget. 2013;4(10):1737–1747. doi:10.18632/oncotarget.1408. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
83. Yamash*ta AS, da Costa RM, Borodovsky A, Festuccia WT, Chan T, Riggins GJ. Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide. Neuro-oncology. 2019;21(2):189–200. doi:10.1093/neuonc/noy146. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
84. Chen F, Bian K, Tang Q, Fedeles BI, Singh V, Humulock ZT, et al. Oncometabolites d-and l-2-hydroxyglutarate inhibit the AlkB family DNA repair enzymes under physiological conditions. Chem Res Toxicol. 2017;30(4):1102–1110. doi:10.1021/acs.chemrestox.7b00009. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
85. Pang Y, Lu Y, Caisova V, Liu Y, Bullova P, Huynh T-T, et al. Targeting NAD+/PARP DNA repair pathway as a novel therapeutic approach to sdhb-mutated cluster i pheochromocytoma and paragangliomacombination therapy for pheochromocytoma and paraganglioma. Clinical Cancer Research. 2018;24(14):3423–3432. doi:10.1158/1078-0432.CCR-17-3406. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
86. Lu Y, Liu Y, Pang Y, Pacak K, Yang C. Double-barreled gun: Combination of PARP inhibitor with conventional chemotherapy. Pharmacol Ther. 2018;188:168–175. doi:10.1016/j.pharmthera.2018.03.006. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
87. Lu Y, Kwintkiewicz J, Liu Y, Tech K, Frady LN, Su YT, et al. Chemosensitivity of IDH1-mutated gliomas due to an impairment in parp1-mediated dna repair. Cancer Res. 2017;77(7):1709–1718. doi:10.1158/0008-5472.CAN-16-2773. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
88. Wang Y, Wild AT, Turcan S, Wu WH, Sigel C, Klimstra DS, et al. Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas. Sci Adv. 2020;6(17):eaaz3221. doi:10.1126/sciadv.aaz3221. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
89. Ducray F, Sanson M, Chinot OL, Fontanilles M, Rivoirard R, Thomas-Maisonneuve L, et al. Olaparib in recurrent IDH-mutant high-grade glioma (OLAGLI) J Clin Oncol. 2021;39(15_suppl):2007. doi:10.1200/JCO.2021.39.15_suppl.2007. [CrossRef] [Google Scholar]
90. Fanucci K, Pilat MJP, Shah R, Boerner SA, Li J, Durecki DE, et al. Multicenter phase 2 trial of the PARP inhibitor (PARPi) olaparib in recurrent IDH1 and IDH2-mutant contrast-enhancing glioma. J Clin Oncol. 2022;40(16_suppl):2035–2035. doi:10.1200/JCO.2022.40.16_suppl.2035. [CrossRef] [Google Scholar]
91. Schumacher T, Bunse L, Pusch S, Sahm F, Wiestler B, Quandt J, et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature. 2014;512(7514):324–327. doi:10.1038/nature13387. [PubMed] [CrossRef] [Google Scholar]
92. Wang Z, Zhang C, Liu X, Wang Z, Sun L, Li G, et al. Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma. Oncoimmunology. 2016;5(11):e1196310. doi:10.1080/2162402X.2016.1196310. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
93. Kohanbash G, Carrera DA, Shrivastav S, Ahn BJ, Jahan N, Mazor T, et al. Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas. J Clin Invest. 2017;127(4):1425–1437. doi:10.1172/JCI90644. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
94. Bunse L, Pusch S, Bunse T, Sahm F, Sanghvi K, Friedrich M, et al. Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate. Nat Med. 2018;24(8):1192–1203. doi:10.1038/s41591-018-0095-6. [PubMed] [CrossRef] [Google Scholar]
95. Kadiyala P, Carney SV, Gauss JC, Garcia-Fabiani MB, Haase S, Alghamri MS, et al. Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in mice. J Clin Invest. 2021;131(4):e139542. doi:10.1172/JCI139542. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
96. Pellegatta S, Valletta L, Corbetta C, Patanè M, Zucca I, Riccardi Sirtori F, et al. Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma. Acta Neuropathol Commun. 2015;3(1):1–12. doi:10.1186/s40478-014-0180-0. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
97. Platten M, Schilling D, Bunse L, Wick A, Bunse T, Riehl D, et al. ATIM-33. NOA-16: a first-in-man multicenter phase I clinical trial of the German Neurooncology working group evaluating a mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant ASTROCYTOMAS. Neuro-oncology. 2018;20(suppl_6):vi8–vi9. doi:10.1093/neuonc/noy148.028. [CrossRef] [Google Scholar]
